Lipocine Inc. (LPCN): Price and Financial Metrics
GET POWR RATINGS... FREE!
LPCN Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for LPCN is 0.01 -- better than merely 9.18% of US stocks.
- LPCN's price/sales ratio is 568.42; that's higher than the P/S ratio of 99.01% of US stocks.
- The volatility of Lipocine Inc's share price is greater than that of 92.61% US stocks with at least 200 days of trading history.
- Stocks with similar financial metrics, market capitalization, and price volatility to Lipocine Inc are ONCT, ETON, HTBX, QUIK, and CDXS.
- LPCN's SEC filings can be seen here. And to visit Lipocine Inc's official web site, go to www.lipocine.com.
LPCN Stock Price Chart Interactive Chart >
LPCN Price/Volume Stats
|Current price||$1.12||52-week high||$2.42|
|Prev. close||$1.12||52-week low||$1.03|
|Day high||$1.14||Avg. volume||2,429,065|
|50-day MA||$1.31||Dividend yield||N/A|
|200-day MA||$1.46||Market Cap||98.89M|
Lipocine Inc. (LPCN) Company Bio
Lipocine develops pharmaceutical products using its oral drug delivery technology in the areas of mens and womens health, with a current focus being testosterone replacement. The company was founded in 1997 and is based in Salt Lake City, Utah.
Most Popular Stories View All
LPCN Latest News Stream
|Loading, please wait...|
LPCN Latest Social Stream
View Full LPCN Social Stream
Latest LPCN News From Around the Web
Below are the latest news stories about Lipocine Inc that investors may wish to consider to help them evaluate LPCN as an investment opportunity.
Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will present at the Cantor Fitzgerald Virtual Global Healthcare Conference. The conference will be held virtually. Presentation details are below.
Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13-15, 2021.
By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT LiFT Liver Biopsy Results On August 25 th , 2021 Lipocine (NASDAQ:LPCN) released liver biopsy results for its Phase II LiFT study in NASH. LiFT , or Liver Fat Intervention with Oral Testosterone, is a Phase II clinical study designed to evaluate LPCN 1144 oral testosterone in men with biopsy-confirmed NASH. Primary endpoint
Lipocine's LPCN 1144 Met Non-Alcoholic Steatohepatitis ("NASH") Resolution Regulatory Endpoint in Phase 2 LiFT Study
Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced positive topline 36-week results from its Phase 2 proof of concept LiFT ("Liver Fat intervention with oral Testosterone") clinical study, NCT04134091, investigating LPCN 1144 in men with biopsy-confirmed NASH. Currently, there are no approved treatments for NASH, a leading cause of liver failure and liver transplantation globally. LPCN 1144 comprises an orally de
By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT Second Quarter 2021 Financial and Operational Results On August 5 th , 2021 Lipocine (NASDAQ:LPCN) filed its Form 10-Q and posted its earnings release for the three month period ending June 30, 2021. Highlights for the second quarter 2021 and to-date include: ➢ Summary judgment in patent infringement lawsuit – May 2021 ➢ IND
LPCN Price Returns